Last updated on October 2018

Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer


Brief description of study

The purpose of study is to compare the efficacy and safety of ONO-4538 in combination with carboplatin, paclitaxel, and bevacizumab (ONO-4538 group) to placebo in combination with carboplatin, paclitaxel, and bevacizumab (placebo group) in chemotherapy-nave subjects with stage IIIB/IV or recurrent non-squamous non-small cell lung cancer unsuitable for radical radiation in a multicenter, randomized, double-blind study.

Clinical Study Identifier: NCT03117049

Contact Investigators or Research Sites near you

Start Over

Ono Pharmaceutical Co. Ltd Corporate ...

Shizuoka Clinical Site
Sunto-gun, Japan
  Connect »